Aditxt, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ADTX Nasdaq 2836 www.aditxt.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aditxt, Inc.

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc. - Nov 19th, 2024 12:17 pm
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 - Nov 14th, 2024 9:36 pm
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025 - Nov 14th, 2024 12:15 pm
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares - Nov 8th, 2024 1:30 pm
Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders - Nov 7th, 2024 1:30 pm
Appili Therapeutics Announces Results of Special Meeting of Shareholders - Nov 6th, 2024 10:55 pm
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem - Nov 6th, 2024 1:30 pm
Evofem Secures Investor Support for Proposed Merger through Voting Agreements - Nov 6th, 2024 1:00 pm
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - Oct 31st, 2024 12:30 pm
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - Oct 31st, 2024 11:15 am
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time - Oct 30th, 2024 9:00 pm
Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives - Oct 29th, 2024 12:15 pm
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem - Oct 28th, 2024 12:15 pm
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time - Oct 21st, 2024 12:15 pm
Aditxt CEO Clarifies NASDAQ Compliance and Capital Strategy - Oct 12th, 2024 9:28 pm
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval - Oct 10th, 2024 12:15 pm
Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time - Oct 9th, 2024 2:52 pm
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem - Oct 8th, 2024 12:15 pm
Aditxt Delivers Shareholder Update and 2024 Year-End Plan - Oct 3rd, 2024 12:15 pm
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024 - Sep 27th, 2024 12:15 pm